Provention Bio Inc
NASDAQ:PRVB
Earnings Announcements
Provention Bio Announces Positive Final Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate Prv-101
Published: 03/28/2022 11:52 GMT
Provention Bio Inc (PRVB) - Provention Bio Announces Positive Final Results From First-in-human Study of Coxsackievirus B Vaccine Candidate Prv-101.
Provention Bio Inc - Prv-101 Continued to Be Well Tolerated.
Provention Bio Inc - Prv-101 Met Primary Endpoint Confirming Tolerability Observed in Previously Reported Interim Analysis.
Provention Bio Inc - Results Also Showed Durability of Viral Neutralizing Antibody (vnt) Responses.
Provention Bio Inc - Prv-101 Continued to Be Well Tolerated.
Provention Bio Inc - Prv-101 Met Primary Endpoint Confirming Tolerability Observed in Previously Reported Interim Analysis.
Provention Bio Inc - Results Also Showed Durability of Viral Neutralizing Antibody (vnt) Responses.
Revenue is expected to be $0.73 Million
Adjusted EPS is expected to be -$0.50
Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.72
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.50
Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.72
More details on our Analysts Page.